Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 5
2004 2
2005 3
2006 6
2007 1
2008 2
2009 6
2010 3
2011 3
2012 3
2013 4
2014 2
2015 2
2016 5
2017 4
2018 4
2019 5
2020 4
2021 11
2022 9
2023 9
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Increased lentivirus titer using ultra expression vectors.
Fujibayashi S, Kiyono T, Endo Y, Tani T, Tate H, Bai L, Sugano E, Tomita H, Fukuda T. Fujibayashi S, et al. Among authors: sugano e. Anal Biochem. 2023 May 15;669:115119. doi: 10.1016/j.ab.2023.115119. Epub 2023 Mar 21. Anal Biochem. 2023. PMID: 36958509
Near-infrared (NIR) up-conversion optogenetics.
Hososhima S, Yuasa H, Ishizuka T, Hoque MR, Yamashita T, Yamanaka A, Sugano E, Tomita H, Yawo H. Hososhima S, et al. Among authors: sugano e. Sci Rep. 2015 Nov 10;5:16533. doi: 10.1038/srep16533. Sci Rep. 2015. PMID: 26552717 Free PMC article.
Differences in patients' population and efficacy/effectiveness of biologic disease-modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis - using the IORRA cohort.
Sugano E, Tanaka E, Inoue E, Sakai R, Abe M, Saka K, Sugitani N, Ochiai M, Yamaguchi R, Higuchi Y, Sugimoto N, Ikari K, Nakajima A, Yamanaka H, Harigai M. Sugano E, et al. Mod Rheumatol. 2022 Jul 1;32(4):675-685. doi: 10.1093/mr/roab067. Mod Rheumatol. 2022. PMID: 34918127 Review.
Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data.
Tanaka E, Inoue E, Shoji A, Nilsson J, Papagiannopoulos C, Dhanda D, Yoshizawa Y, Abe M, Saka K, Sugano E, Sugitani N, Ochiai M, Yamaguchi R, Ikari K, Yamanaka H, Harigai M. Tanaka E, et al. Among authors: sugano e. PLoS One. 2022 Nov 16;17(11):e0277566. doi: 10.1371/journal.pone.0277566. eCollection 2022. PLoS One. 2022. PMID: 36383610 Free PMC article.
91 results